ISSN 1662-4009 (online)

ESPE Yearbook of Paediatric Endocrinology (2018) 15 15.6 | DOI: 10.1530/ey.15.15.6


To read the full abstract: N Engl J Med 2017;377:28-40

We highlight this paper for 3 reasons. First, remarkably there are few robust data on effective treatment options for endometriosis. Subcutaneous GnRH antagonists are sometimes used off-label, but with very limited evidence. Secondly, the clear findings here confirm the pathogenesis of endometriosis as being driven by an over-active hypothalamo-pituitary-ovarian axis, and support the rationale for other therapeutic options to reduce ovulation and suppress circulating estradiol levels. Thirdly, could there be other childhood indications for an oral GnRH antagonist treatment? Unlike our traditional therapy, GnRH analogues, which cause profound depletion of pituitary gonadotrophins and estradiol levels after an initial surge, this GnRH antagonist rapidly reduces gonadotrophin and estradiol levels, particularly at the higher dose. Treatments for precocious puberty or to extend the duration of puberty and associated adolescent growing window might be possible uses to test in future trials.

Article tools

My recent searches

No recent searches.

Authors